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Background 
Systemic sclerosis (SSc) and sarcoidosis are both uncommon connective tissue diseases (CTD) with reported prevalence of about 3.08 in 100,000 (1) and 20 in 100,000 (2) respectively. Case reports and a recent review suggest an 
association between the two diseases as well as the possibility that the CTD may trigger granulomatous inflammation (3). We evaluated the prevalence and clinical features of patients with both these diseases. 
 
Methods 
We retrospectively examined the clinical database of all SSc patients (n≈2500) in our centre over the last 12 years.  
 
Results 
We identified a sub-cohort of 827 patients. From these, 11 patients (1.33%) were found to have both SSc and sarcoidosis. The median age was 63.0±11.2 (years±SD). The majority of patients (63.7%) were Caucasians. The diagnosis of 
sarcoidosis preceded SSc in 7 patients and was contemporaneous in one patient. The median interval for diagnosis between the two diseases was 14.0±11.4 years. All patients, but one, were anti-nuclear antibodies (ANA) positive with 
homogenous pattern identified in 5 patients (45.5%) and centromere pattern in 4 (36.4%). Extra-nuclear antibodies (ENA) were positive in 5 patients, mainly anti-Scl70 (36.4%). Sarcoidosis was biopsy proven in 6 patients, one had a positive 
Kveim test and 4 were considered to have sarcoidosis based on clinical features and supportive investigations. Five patients had single-organ involvement related to sarcoidosis (lung, lacrimal gland, lymph nodes). Interstitial lung disease 
(ILD) was present in 5 patients (45.5%), a majority of these harboured anti-Scl70 antibodies. 40% of these had radiological changes attributable to both diseases and the remaining 3 patients had changes related to SSc or sarcoidosis alone. 




The data suggests that the observed prevalence for coexisting diseases is higher than expected. Interestingly, the gender preponderance is more similar to that observed in SSc than sarcoidosis (4,5). In contrast to recent review, a majority in 
this cohort had sarcoidosis prior to SSc suggesting that it is less likely that SSc may be associated with granulomatous formation (3). The pulmonary involvement shared between the two diseases is consistent with the concept of similar 
aetiopathogenesis for SSc and sarcoidosis. 
 
Case Gender Age Race SSc subset Sarcoidosis involvement 
Year of diagnosis 
Major organ involvement Lung disease ANA ENA Immunossupression 
SSc Sarcoidosis 
1 F 65 Ca lcSSc Lung + LN  1988 1970 - - H - - 
2 F 64 Ca dcSSc Lung 1984 1995 ILD NSIP H Scl70 Previous AZA 
3 F 49 Ca lcSSc Lung + LN 1982 2008 ILD Sarcoid nodules - - - 
4 F 66 W/B lcSSc Lung + Skin 2000 1994 ILD NSIP H Scl70 MMF + Steroids 
5 M 36 W/A lcSSc Lung + LN 2007 2006 Suspected cardiac sarcoidosis - FS PM/Scl MMF + Steroids 
6 F 66 Ca lcSSc Lacrimal glands 2008 1994 - - C - - 
7 M 73 Ca lcSSc Lung + LN 2009 1978 - - C - - 
8 F 45 Ca lcSSc Lung 2002 2002 ILD 
NSIP + Sarcoid nodules 
 
H Scl70 MMF + Steroids 
9 M 63 Ca lcSSc LN + Eye 2006 1975 PAH - C - - 
10 F 50 B dcSSc Lung 2011 2008 ILD 
NSIP + Sarcoid nodules 
 
H Scl70 Steroids 
11 F 60 I lcSSc LN 1999 2013 PAH - C - - 
Table 1: Table 1. Patient’s clinical and analytical features.. 
F – female; M – male; Ca – caucasian; W/B – mixed caucasian and african-american; W/A – mixed caucasian and asian; B – african-american; I – indian; lcSSc – limited cutaneous systemic sclerosis; dcSSc – diffuse cutaneous systemic sclerosis; LN – lymph nodes; ILD – interstitial lung disease; PAH – pulmonary arterial 
hypertension; NSIP – non-specific interstitial pneumonia; H – homogenous; FS – fine speckled; C – centromere; AZA – azathioprine; MMF – mycophenolate mofetil 
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